The smoke is still clearing from three federal district judges’ recent decisions in drug manufacturers Lilly, Sanofi, Novo Nordisk, Novartis, and United Therapeutics’ 340B contract pharmacy lawsuits. In the rulings’ wake, we are keeping close tabs on what happens next
…
A hospital group says two federal district judges got it right, but one got it wrong, on whether drug manufacturers are legally bound to provide 340B drug discounts for drugs dispensed at contract pharmacies.
In a Nov. 6 statement, 340B
…
A new research letter published in JAMA Internal Medicine found substantial variation among 17 “top-performing” hospitals—14 of them enrolled in 340B—in what they charge commercial insurers for clinician-administered drugs.
Meanwhile, new research published in Journal of Healthcare Quality found that
…
A federal district judge last night issued the second court ruling of the day involving drug manufacturers’ denials of and limitations on 340B pricing when covered entities use contract pharmacies. Like the day’s earlier ruling, this one too was mixed,
…
A federal district judge this afternoon upheld the federal government’s finding that drug manufacturers Sanofi and Novo Nordisk cannot unilaterally impose restrictions on offers of 340B pricing to covered entities and that their policies must cease.
U.S. Chief District Judge
…
The federal government on Tuesday urged the judges in AstraZeneca, Novartis, Novo Nordisk, Sanofi, and United Therapeutics’ separate 340B contract pharmacy lawsuits to follow the lead of the judge in Lilly’s case and hold that these five companies’ contract pharmacy
…
President Biden yesterday nominated the federal district judge assigned to AstraZeneca’s 340B contract pharmacy lawsuit to fill a vacancy on a federal appeals court in Washington, D.C.
The White House announced U.S. District Judge Leonard Stark’s nomination to be a
…
Drug discount management company Kalderos sent email messages to 340B hospitals this week once again announcing the launch of its 340B Pay service to let drug companies pay 340B ceiling prices as back-end rebates instead of as front-end discounts on
…
Democratic lawmakers have come to an agreement for placing a limited drug price negotiation plan for the Medicare program into the Build Back Better bill, but how it will impact the 340B program remains to be seen.
“By empowering Medicare
…SPONSORED CONTENT
The Net Promoter Score® (NPS) offers an objective measurement of what is arguably one of healthcare’s most critical—but subjective—areas of focus: patient satisfaction. It is a cross-industry standardized index designed to measure people’s willingness to recommend a company’s products or services to others. While traditional customer satisfaction surveys usually measure a
…
×
*Sign up for news summaries and alerts from 340B Report
